Clarity Engagement Solutions
APRIL 26, 2021
To the non-pharma world, it’s easy to assume that the picture should be bright for pharmaceutical companies producing medicine for a more sickened population with more complex needs. Pharmaceutical companies and their commercial teams are not exactly known for being nimble and adaptable in times of extreme change.
Clarity Engagement Solutions
APRIL 26, 2021
To the non-pharma world, it’s easy to assume that the picture should be bright for pharmaceutical companies producing medicine for a more sickened population with more complex needs. Pharmaceutical companies, their commercial and brand teams are not exactly known for being nimble and adaptable in times of change.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarity Engagement Solutions
APRIL 26, 2021
The COVID-19 pandemic has now intensified and dragged out into the light of day, the stark disparity between the legacy product promotion objectives of pharma and the tectonic shifts in strategy being forced on healthcare decision makers.
Clarity Engagement Solutions
APRIL 26, 2021
To the non-pharma world, it’s easy to assume that the picture should be bright for pharma organizations producing medicine for a more sickened population with more complex needs. And conversely, the propensity for commercial failure in pharma if those needs are not well-understood post-pandemic, has increased substantially as well.
Expert insights. Personalized for you.
91 
Let's personalize your content